Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas (EPL)

This study has been completed.
The Atlantic Philanthropies
Australian Department of Industry, Tourism and Resources
British Society for Haematology
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Maher Gandhi, Queensland Institute of Medical Research
ClinicalTrials.gov Identifier:
First received: October 22, 2008
Last updated: May 21, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)